Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K announcing a Learning Theater presentation at CHEST 2026 on October 21, 2026, high | Oct 15, 2026 |
| AAPG | 6-K | neutral | 1/10 | Ascentage Pharma's trustee purchased 200,000 existing shares (0.05% of issued shares) on-market for HK$5.78 million (~HK | Oct 15, 2026 |
| EDSA | 8-K | neutral | 4/10 | Edesa Biotech announced FDA clearance of its IND application for EB06, a monoclonal antibody targeting CXCL10, enabling | Oct 15, 2026 |
| EDSA | PRESS-RELEASE | neutral | 4/10 | Edesa Biotech announced FDA clearance of its IND for EB06, a monoclonal antibody targeting CXCL10, enabling expansion of | Oct 15, 2026 |
| PBM | SC 13D/A | neutral | 5/10 | Psyence Labs Ltd. filed Amendment No. 1 to its Schedule 13D, reporting the acquisition of 1,497,500 common shares of Psy | Oct 15, 2026 |
| MXCT | SC 13D | bullish | 6/10 | Liontrust Investment Partners LLP, a UK-based investment firm, filed a Schedule 13D disclosing beneficial ownership of 5 | Oct 15, 2026 |
| PLX | SC 13G | neutral | 3/10 | HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed a Schedule 13G disclosing a passive 5.2% sta | Oct 15, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/sh | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 5/10 | Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program co | Oct 15, 2026 |
| VVOS | 8-K | mixed | 6/10 | Vivos Therapeutics entered into a definitive agreement to acquire an 11% fully diluted equity stake in SOD Sciences and | Oct 15, 2026 |
| VVOS | PRESS-RELEASE | neutral | 5/10 | Vivos Therapeutics issued 12,000 shares of Series C Convertible Preferred Stock (stated value $12M) to acquire an 11% eq | Oct 15, 2026 |
| EVO | 6-K | bearish | 6/10 | Evotec SE announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Management Board member, effe | Oct 15, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 5/10 | TOMI announced independent lab results showing SteraMist iHP sharply reduces Listeria monocytogenes in biofilm (flat sur | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | bearish | 6/10 | Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data u | Oct 15, 2026 |
| RXRX | 424B5 | bearish | 6/10 | Recursion Pharmaceuticals is filing a preliminary prospectus supplement for a $200 million underwritten public offering | Oct 15, 2026 |
| OCGN | 8-K | neutral | 5/10 | Ocugen posted an October 2026 corporate presentation on its website, providing a pipeline update across three gene thera | Oct 15, 2026 |
| LEGN | 6-K | bullish | 5/10 | Legend Biotech announced FDA clearance of its IND application for LB2501, a first-in-class dual-targeting (CD19/CD20) in | Oct 15, 2026 |
| JSPR | 8-K | neutral | 3/10 | Jasper Therapeutics completed enrollment of the IgA nephropathy (IgAN) cohort in its Phase 2 basket study of vensobafusp | Oct 15, 2026 |
| JSPR | PRESS-RELEASE | bearish | 7/10 | Jasper Therapeutics announced completion of enrollment in the IgAN cohort of its Phase 2 basket study for vensobafusp al | Oct 15, 2026 |
| TRAX | PRESS-RELEASE | bearish | 6/10 | First Tracks Biotherapeutics announced a $200M private placement of 6.1M shares at $32.75/share, with proceeds for gener | Oct 15, 2026 |
| TARA | PRESS-RELEASE | neutral | 3/10 | Protara Therapeutics completed enrollment of the Phase 2b dose confirmation cohort (24 patients) in the THRIVE-3 registr | Oct 15, 2026 |
| HUMA | PRESS-RELEASE | bullish | 5/10 | Humacyte provided a Q3 2026 commercial update highlighting accelerating Symvess adoption, with hospitals ordering the pr | Oct 15, 2026 |
| MESO | 6-K | neutral | 2/10 | Mesoblast filed a routine 6-K with the ASX on October 14, 2026, reporting the cessation of certain securities, the issue | Oct 15, 2026 |
| HELP | PRESS-RELEASE | neutral | 3/10 | Helus Pharma appointed Dr. Suresh Durgam, a CNS drug-development executive with FDA approval experience (CAPLYTA), to it | Oct 15, 2026 |
| PVLA | PRESS-RELEASE | neutral | 4/10 | Palvella Therapeutics announced poster presentations at the PeDRA Annual Conference featuring new pediatric analyses fro | Oct 15, 2026 |
| AQST | 8-K | bullish | 7/10 | Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphy | Oct 15, 2026 |
| SPRC | PRESS-RELEASE | neutral | 3/10 | SciSparc announced a strategic shift toward Agentic AI-powered technologies, including cybersecurity and finance, while | Oct 15, 2026 |
| KRYS | 8-K | bullish | 6/10 | Krystal Biotech announced positive proof-of-concept clinical data for KB113, an intratumoral immunotherapy for basal cel | Oct 15, 2026 |
| TNXP | 8-K | bullish | 5/10 | Tonix Pharmaceuticals disclosed preliminary Q3 2026 TONMYA net revenue of $14M-$15M, up 27-36% sequentially from Q2's $1 | Oct 15, 2026 |